Electro-gene therapy of arthritis by using an expression plasmid encoding the soluble p75 tumor necrosis factor receptor-Fc fusion protein
OwnerJong-Mook Kim, Seong-Hyun Ho +3inventors
InventorsJong-Mook Kim, Seong-Hyun Ho, Woong Hahn, Seung-Shin Yu, Sunyoung Kim
Life of this patent
Estimating the term…
Abstract
The electroporation-mediated delivery of plasmid containing cDNA for soluble p75 TNF (tumor necrosis factor) receptor linked to the Fc portion of human IgG1 (sTNFR:Fc) can be effectively used for the treatment of arthritis in a mammal.
Claims12
A pharmaceutical composition for electro-gene therapy of arthritis in a mammal, which comprises a therapeutically effective amount of a DNA encoding soluble p75 TNF (tumor necrosis factor) receptor linked to the Fc portion of human IgG1 (sTNFR:Fc) and a pharmaceutically acceptable carrier.
A method for electro-gene therapy of arthritis in a mammal, which comprises administering a therapeutically effective amount of a DNA encoding sTNFR:Fc via in vivo electroporation.
Dependencies are inferred from the claim text.